KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Stereotaxis (STXS) Research & Development (2016 - 2025)

Historic Research & Development for Stereotaxis (STXS) over the last 17 years, with Q3 2025 value amounting to $2.5 million.

  • Stereotaxis' Research & Development rose 374.9% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 306.03%. This contributed to the annual value of $9.8 million for FY2024, which is 499.37% down from last year.
  • Per Stereotaxis' latest filing, its Research & Development stood at $2.5 million for Q3 2025, which was up 374.9% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Stereotaxis' Research & Development peaked at $2.9 million during Q2 2022, and registered a low of $1.8 million during Q2 2025.
  • For the 5-year period, Stereotaxis' Research & Development averaged around $2.5 million, with its median value being $2.5 million (2021).
  • Per our database at Business Quant, Stereotaxis' Research & Development soared by 3743.45% in 2021 and then tumbled by 2182.14% in 2025.
  • Quarter analysis of 5 years shows Stereotaxis' Research & Development stood at $2.6 million in 2021, then dropped by 8.22% to $2.4 million in 2022, then fell by 7.83% to $2.2 million in 2023, then increased by 26.13% to $2.8 million in 2024, then dropped by 8.75% to $2.5 million in 2025.
  • Its Research & Development stands at $2.5 million for Q3 2025, versus $1.8 million for Q2 2025 and $2.4 million for Q1 2025.